ReCor Medical Expands Its Medical Advisory Board

Key opinion leaders (KOLs) share their perspective on renal denervation for treating resistant hypertension, a major risk factor for cardiovascular disease

MENLO PARK, Calif.--()--Click here for video interviews

ReCor Medical announced today that it has expanded its medical advisory board in anticipation of conducting post-market clinical studies of its next-generation PARADISE® System for treatment of resistant hypertension via renal denervation—the only system for renal denervation that is based on ultrasound, not radiofrequency, energy. The new medical advisors are: Peter J. Fitzgerald, M.D., Ph.D., Stanford University School of Medicine, Stanford, Calif.; Thomas Mabin, M.D., Vergelegen Medi-Clinic, South Africa; Krishna J. Rocha-Singh, M.D., Praririe Cardiovascular, Springfield, Ill; and Karl-Heinz Kuck, M.D., Ph.D., Asklepios Klinik, Hamburg, Germany.

ReCor’s medical advisory board also includes: Raoul Bonan, M.D., Montreal Heart Institute; Montreal, Quebec, Canada; Marc R. Sapoval, M.D., Ph.D., Hôpital Européen, Georges-Pompidou, Paris, France; Gilles Montalescot, M.D., Ph.D., Pitié-Salpétrière Hospital, Paris; Carlos E. Ruiz, M.D., Ph.D., Lennox Hill Heart & Vascular Institute, New York City; and, Renu Virmani, M.D., CVPath Institute, Gaithersburg, Maryland.

“We are very excited to add these outstanding physicians to our rapidly expanding medical advisory board. Because early clinical results strongly suggest a significant competitive advantage for ReCor’s ultrasound-based PARADISE system compared to radiofrequency-based standard of care for treating resistant hypertension patients, we look forward to our medical advisors’ special expertise in planning for ReCor’s post-market clinical studies,” said Mano Iyer, CEO, ReCor Medical.

The PARADISE ultrasound catheter was designed with the aim to allow complete circumferential denervation more consistently and efficiently than the standard of care radiofrequency ablation catheter. The procedure with the PARADISE system only requires 30 seconds of energy delivery per treatment location, thereby dramatically reducing the overall procedure time.

ReCor has published a collection of video interviews conducted during ‘EuroPCR 2012’ with key opinion leaders (KOLs) on the topic of RENAL DENERVATION to treat resistant hypertension. (Click link above to see these videos.)

About ReCor Medical, Inc.

Founded in 2009, ReCor is a private venture-backed, early-stage company developing novel therapeutic ultrasound catheter technology. ReCor is backed by European and U.S. investors including Sofinnova Partners, one of the largest life science investors in Europe. The Company’s PARADISE™ technology for renal denervation is CE-marked. For more information about ReCor Medical, please visit the Company’s website at www.recormedical.com.

NOTE: PARADISE™ is approved for sale in Europe; it is not approved for sale or investigational use in the United States.

Contacts

Ronald Trahan Associates Inc.
Ronald Trahan, APR, +1-508-359-4005, x108
President

Sharing

Contacts

Ronald Trahan Associates Inc.
Ronald Trahan, APR, +1-508-359-4005, x108
President